-
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
NCT07266831 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 55 locations
-
A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission
NCT05719441 ·
Phase: Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 36 locations
-
A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia
NCT07681089 ·
Phase: Phase 2 ·
Ages: 18 Years to 79 Years ·
Sex: Male · 3 locations
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
NCT07202546 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 123 locations
-
A Phase Ⅱa Clinical Study of CL-197 Capsules
NCT07308782 ·
Phase: Phase 2 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female) · 1 location
-
A Randomised Placebo Controlled Trial of ART Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs).
NCT04319367 ·
Phase: Phase 2 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female) · 12 locations
-
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
NCT06736613 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 7 locations
-
A Study to Evaluate JL18008 in Subject With HIV Immunological Non-Responders
NCT07579741 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV
NCT07143968 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 10 locations
-
A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1
NCT07275606 ·
Phase: Phase 1, Phase 2 ·
Ages: Up to 10 Days ·
Sex: All (male and female) · 1 location
-
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
NCT04941274 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 99 Years ·
Sex: All (male and female) · 1 location
-
Administration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among People Living With HIV on ART
NCT05668026 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
An Integrated Intervention Using a Pill Ingestible Sensor System
NCT06480578 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Antiviral Clinical Trial for Long Covid-19
NCT06511063 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants
NCT06206564 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion
NCT04147286 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
B-PaLMZ for TB Meningitis
NCT07227779 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
Baricitinib for Reduction of HIV - CNS
NCT05452564 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 2 locations
-
Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB
NCT06568484 ·
Phase: Phase 2, Phase 3 ·
Ages: No age limits stated ·
Sex: All (male and female) · 8 locations
-
Boosting Olfactory and Sensory Training Study (BOOST)
NCT07221123 ·
Phase: Phase 2 ·
Ages: 40 Years and older ·
Sex: All (male and female) · 1 location
-
CAR-T Cells for HIV Infection
NCT04648046 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 2 locations
-
COVID-19 Booster and IIV Schedule in Immunocompromised Hosts
NCT06599658 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 3 locations
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
NCT05488431 ·
Phase: Phase 2 ·
Ages: 40 Years and older ·
Sex: All (male and female) · 3 locations
-
Clinical Trial to Evaluate the Efficacy and Safety of Codivir® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral-naïve Participants
NCT06676410 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Colchicine to Reduce Coronary Artery Inflammation in People With HIV
NCT07704164 ·
Phase: Phase 2 ·
Ages: 50 Years and older ·
Sex: All (male and female) · 4 locations
-
Combination Vaccination and Broadly Neutralising Antibody Therapy in HIV
NCT07054931 ·
Phase: Phase 2 ·
Ages: 18 Years to 64 Years ·
Sex: All (male and female) · 3 locations
-
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
NCT02479698 ·
Phase: Phase 2 ·
Ages: No age limits stated ·
Sex: All (male and female) · 1 location
-
DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road)
NCT06034938 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 4 locations
-
Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
NCT05907759 ·
Phase: Phase 2 ·
Ages: 18 Years to 120 Years ·
Sex: All (male and female) · 1 location
-
Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)
NCT04375800 ·
Phase: Phase 2 ·
Ages: 4 Weeks to 11 Years ·
Sex: All (male and female) · 24 locations
-
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
NCT04499053 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 4 locations
-
Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study
NCT05652478 ·
Phase: Phase 2 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female) · 1 location
-
Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy
NCT07336797 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV
NCT05514899 ·
Phase: Phase 2 ·
Ages: 21 Years to 70 Years ·
Sex: All (male and female) · 1 location
-
Efficacy and Safety of ACC017 Tablets Compared With Dolutegravir Sodium Tablets in Treatment-Naïve Adults With Human Immunodeficiency Virus Type 1 (HIV-1)
NCT07711223 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Efficacy, Safety and Pharmacokinetics of DTG with RIF
NCT03731559 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 10 locations
-
Enhancing Smoking Cessation for African American People Everywhere
NCT07024992 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
NCT06624839 ·
Phase: Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: Male · 2 locations
-
Evaluating Smoking Cessation Interventions for PWH in South Africa
NCT05413122 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Evaluating the Safety and Immunogenicity of MTBVAC
NCT05947890 ·
Phase: Phase 2 ·
Ages: 12 Years to 55 Years ·
Sex: All (male and female) · 16 locations
-
Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV
NCT06691243 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 2 locations
-
Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1
NCT06071767 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 12 locations
-
Exploratory Study of LP-98 for Injection in ART-Naive HIV-Infected Individuals
NCT07433387 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV
NCT07221214 ·
Phase: Phase 2 ·
Ages: 18 Years to 89 Years ·
Sex: All (male and female) · 1 location
-
HIV-1 Infected Patients, Phase II Trial, Dual Combination Doravirine/Raltegravir Open Label
NCT04513626 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis
NCT04521803 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
Imaging Immune Activation in HIV by PET-MR
NCT03684655 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption
NCT05419024 ·
Phase: Phase 2 ·
Ages: 18 Years to 100 Years ·
Sex: All (male and female) · 1 location
-
Immunogenicity and Safety of Hecolin® in HIV Positive/Negative Adults and in Children
NCT06306196 ·
Phase: Phase 2 ·
Ages: 2 Years to 45 Years ·
Sex: All (male and female) · 3 locations
-
Improving Coronary Vascular Health in Women
NCT06843902 ·
Phase: Phase 2 ·
Ages: 45 Years to 75 Years ·
Sex: Female · 1 location
-
Incretin Microdosing for Cardiometabolic Health in People With HIV
NCT07325500 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Inflammation and Depression in People With HIV
NCT05849038 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 2 locations
-
Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy
NCT05187429 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 2 locations
-
Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage
NCT05939167 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 4 locations
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
NCT05288790 ·
Phase: Phase 2 ·
Ages: 18 Years to 89 Years ·
Sex: All (male and female) · 1 location
-
Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without Antiretrovirals
NCT06805656 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
Naltrexone for Overdose Prevention
NCT06633900 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
NCT01419561 ·
Phase: Phase 2 ·
Ages: 18 Years to 120 Years ·
Sex: All (male and female) · 1 location
-
Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV
NCT05570812 ·
Phase: Phase 2 ·
Ages: 18 Years to 85 Years ·
Sex: All (male and female) · 2 locations
-
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide
NCT07040592 ·
Phase: Phase 2 ·
Ages: 18 Years to 99 Years ·
Sex: All (male and female) · 1 location
-
PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma
NCT04303117 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 99 Years ·
Sex: All (male and female) · 1 location
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
NCT05674656 ·
Phase: Phase 1, Phase 2 ·
Ages: 6 Years to 12 Years ·
Sex: All (male and female) · 8 locations
-
Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)
NCT06052618 ·
Phase: Phase 2 ·
Ages: 18 Years to 120 Years ·
Sex: All (male and female) · 1 location
-
Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control
NCT05300035 ·
Phase: Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 17 locations
-
Platform Trial For Cryptococcal Meningitis (PLATFORM-CM)
NCT06666322 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
Propranolol for the Treatment of Kaposi Sarcoma in Adults
NCT06445166 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)
NCT07308886 ·
Phase: Phase 2 ·
Ages: 18 Years to 120 Years ·
Sex: All (male and female) · 1 location
-
Reducing Systemic Inflammation in People on Antiretroviral Therapy
NCT07030920 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults
NCT05835479 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 6 locations
-
SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy
NCT05586581 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female) · 1 location
-
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
NCT05580458 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Small Trial of Alendronate Impact on the Reservoir of HIV
NCT07216794 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 5 locations
-
Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV
NCT07040319 ·
Phase: Phase 1, Phase 2 ·
Ages: 16 Years to 45 Years ·
Sex: Female · 10 locations
-
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
NCT06343311 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
Targeted Therapies for Immunological Non-Responders in People With HIV: A Multicenter Clinical Study
NCT07637877 ·
Phase: Phase 2 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female) · 5 locations
-
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
NCT06554717 ·
Phase: Phase 2 ·
Ages: 50 Years to 80 Years ·
Sex: All (male and female) · 2 locations
-
The Tatelo Plus Study
NCT06508749 ·
Phase: Phase 1, Phase 2 ·
Ages: 24 Weeks to 25 Years ·
Sex: All (male and female) · 2 locations
-
Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis
NCT05590455 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 3 locations
-
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
NCT05470491 ·
Phase: Phase 1, Phase 2 ·
Ages: 12 Years to 120 Years ·
Sex: All (male and female) · 1 location
-
Trial of Ixazomib for Kaposi Sarcoma
NCT04305691 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 11 locations
-
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
NCT02140255 ·
Phase: Phase 1, Phase 2 ·
Ages: Up to 48 Hours ·
Sex: All (male and female) · 46 locations